Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

41.7%

5 terminated/withdrawn out of 12 trials

Success Rate

58.3%

-28.2% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
6(54.5%)
Phase 2
4(36.4%)
Phase 3
1(9.1%)
11Total
Phase 1(6)
Phase 2(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT04220684Phase 1Completed

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

Role: collaborator

NCT04808115Phase 1Withdrawn

IIT PH1 KDS-1001 in Patients With CML

Role: collaborator

NCT02999854Phase 3Terminated

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Role: lead

NCT00248404Phase 1Completed

NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)

Role: lead

NCT04797975Phase 1Withdrawn

Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19

Role: lead

NCT04395092Phase 2Withdrawn

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Role: lead

NCT00967343Phase 2Terminated

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Role: lead

NCT02500550Phase 2Completed

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Role: lead

NCT01794299Phase 2Completed

Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Role: lead

NCT00248365Phase 1Completed

Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)

Role: lead

NCT02188290Completed

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

Role: lead

NCT00993486Phase 1Completed

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Role: lead

All 12 trials loaded